Glycosylation-Related Gene Signature Identifies MFNG as a Key Driver of Proliferation and Metastasis in Colorectal Cancer.

[BACKGROUND] Colorectal cancer (CRC) ranks as the third most common malignancy and second leading cause of cancer-related mortality worldwide. Aberrant glycosylation has emerged as a hallmark of cancer, yet systematic analyses of glycosylation-related gene expression patterns and their prognostic implications in CRC remain limited.

[METHODS] We conducted comprehensive analyses of 214 glycosylation-related genes using TCGA and GEO datasets. Differential expression analysis identified significantly altered genes, followed by LASSO Cox regression to construct a four-gene glycosylation-Related Gene Signature (GRGS). We validated the model across multiple independent cohorts and performed functional experiments with MFNG knockdown in CRC cell lines and zebrafish xenograft models.

[RESULTS] We identified 54 differentially expressed glycosylation-related genes in CRC tissues. The four-gene signature comprising MFNG (manic fringe), UST (uronyl 2-sulfotransferase), SLC35D1 (solute carrier family 35 member D1), and GALNT7 (polypeptide N-acetylgalactosaminyltransferase 7) demonstrated robust prognostic performance across validation cohorts. GRGS-High patients exhibited significantly shorter overall survival and were associated with advanced tumor stages. MFNG emerged as the top predictor, with high expression correlating with poor survival. Functional validation confirmed that MFNG knockdown significantly inhibited CRC cell proliferation, migration, and invasion both in vitro and in vivo.

[CONCLUSION] Our study establishes GRGS as a reliable prognostic tool for CRC risk stratification and identifies MFNG as a promising therapeutic target. These findings provide valuable insights into glycosylation-mediated CRC progression and offer potential clinical applications for precision oncology.